Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
News|Slideshows|July 17, 2020
Medicare Use of Telehealth During COVID-19
Author(s)Grace Halsey
Medicare beneficiary use of telehealth services reached nearly 9 million as COVID-19 shut down on-site visits. Will the options be permanent?
Advertisement
Use of telehealth by US Medicare beneficiaries during the early weeks of the COVID-19 pandemic reached more than 9 million as in-person clinical contact quickly become impossible, according to data from the Centers for Medicare & Medicaid Services (CMS). CMS also reports that weekly telehealth visits jumped from 13 000 pre-pandemic to nearly 1.7 million in April.
In a July 15 commentary in Health Affairs, CMS administrator Seema Verma elaborated on the swift adoption of "connected health" from March 17-June 30. As to the future of state and federal rules relaxed to encourage uptake, Verma said CMS is “reviewing the temporary changes we made and assessing which of these flexibilities should be made permanent through regulatory action.”
The short slide show below highlights the demographcis of telehealth use among Medicare beneficiaries and the issues CMS is considering before deciding on permanent changes.
Advertisement
Related to this article
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Advertisement
Advertisement